Abnormalities of quantities and functions of CD56bright natural killer cells in non-severe aplastic Anemia

References

• Bacigalupo A. How I treat acquired aplastic anemia. Blood. 2017;129(11):1428–1436. doi: 10.1182/blood-2016-08-693481
   PubMed Web of Science ®Google Scholar
• Dezern AE, Brodsky RA. Clinical management of aplastic anemia. Expert Rev Hematol. 2011;4(2):221–230. doi: 10.1586/ehm.11.11
   PubMed Web of Science ®Google Scholar
• Kwon JH, Kim I, Lee YG, et al. Clinical course of non-severe aplastic anemia in adults. Int J Hematol. 2010;91(5):770–775. doi: 10.1007/s12185-010-0601-1
   PubMed Web of Science ®Google Scholar
• Matsuda K, Koya J, Arai S, et al. Cyclosporine therapy in patients with transfusion-independent non-severe aplastic anemia: a retrospective analysis. Intern Med. 2018.
   Web of Science ®Google Scholar
• Iannello A, Débbeche O, Samarani S, et al. Potential role of NK cells in future anti-tumor immunotherapies. Med Sci (Paris). 2007;23(5):502–508. doi: 10.1051/medsci/2007235502
   PubMed Web of Science ®Google Scholar
• Lünemann A, Lünemann JD, Münz C. Regulatory NK-cell functions in inflammation and autoimmunity. Mol Med. 2009;15(9–10):352–358. doi: 10.2119/molmed.2009.00035
   PubMed Web of Science ®Google Scholar
• Wendt K, Wilk E, Buyny S, et al. Gene and protein characteristics reflect functional diversity of CD56dim and CD56bright NK cells. J Leukoc Biol. 2006;80(6):1529–1541. doi: 10.1189/jlb.0306191
   PubMed Web of Science ®Google Scholar
• Cooper MA, Fehniger TA, Turner SC, et al. Human natural killer cells: a unique innate immunoregulatory role for the CD56(bright) subset. Blood. 2001;97(10):3146–3151. doi: 10.1182/blood.V97.10.3146
   PubMed Web of Science ®Google Scholar
• Gross CC, Schulte-Mecklenbeck A, Wiendl H, et al. Regulatory functions of natural killer cells in multiple sclerosis. Front Immunol. 2016: 7606.
   Google Scholar
• Poli A, Michel T, Thérésine M, et al. CD56bright natural killer (NK) cells: an important NK cell subset. Immunology. 2009;126(4):458–465. doi: 10.1111/j.1365-2567.2008.03027.x
   PubMed Web of Science ®Google Scholar
• Keating SE, Zaiatz-Bittencourt V, Loftus RM, et al. Metabolic reprogramming supports IFN-γ production by CD56bright NK cells. J Immunol. 2016;196(6):2552–2560. doi: 10.4049/jimmunol.1501783
   PubMed Web of Science ®Google Scholar
• Liu C, Li Z, Sheng W, et al. Abnormalities of quantities and functions of natural killer cells in severe aplastic anemia. Immunol Invest. 2014;43(5):491–503. doi: 10.3109/08820139.2014.888448
   PubMed Web of Science ®Google Scholar
• Li XH, Ma J, Wu XX, et al. [Effect of various combinations of IL2, IL12 and IL15 on function of human peripheral blood derived NK cells]. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2009;17(4):918–923.
   Google Scholar
• [Chinese expert consensus on the diagnosis and treatment of aplastic anemia (2017)]. Zhonghua Xue Ye Xue Za Zhi. 2017;38(1):1–5.
   Google Scholar
• Boddu PC, Kadia TM. Updates on the pathophysiology and treatment of aplastic anemia: a comprehensive review. Expert Rev Hematol. 2017;10(5):433–448. doi: 10.1080/17474086.2017.1313700
   PubMed Web of Science ®Google Scholar
• Young NS, Bacigalupo A, Marsh JC. Aplastic anemia: pathophysiology and treatment. Biol Blood Marrow Transplant. 2010;16(1 Suppl):S119–S125. doi: 10.1016/j.bbmt.2009.09.013
   PubMed Web of Science ®Google Scholar
• Fu Y, Gao K, Tao E, et al. Aberrantly expressed long non-coding RNAs In CD8+ T cells response to active tuberculosis. J Cell Biochem. 2017;118(12):4275–4284. doi: 10.1002/jcb.26078
   PubMed Web of Science ®Google Scholar
• Wilusz JE, Sunwoo H, Spector DL. Long noncoding RNAs: functional surprises from the RNA world. Genes Dev. 2009;23(13):1494–1504. doi: 10.1101/gad.1800909
   PubMed Web of Science ®Google Scholar
• Grossman WJ, Verbsky JW, Barchet W, et al. Human T regulatory cells can use the perforin pathway to cause autologous target cell death. Immunity. 2004;21(4):589–601. doi: 10.1016/j.immuni.2004.09.002
   PubMed Web of Science ®Google Scholar
• Michel T, Poli A, Cuapio A, et al. Human CD56bright NK cells: an update. J Immunol. 2016;196(7):2923–2931. doi: 10.4049/jimmunol.1502570
   PubMed Web of Science ®Google Scholar
• Schepis D, Gunnarsson I, Eloranta ML, et al. Increased proportion of CD56bright natural killer cells in active and inactive systemic lupus erythematosus. Immunology. 2009;126(1):140–146. doi: 10.1111/j.1365-2567.2008.02887.x
   PubMed Web of Science ®Google Scholar
• Dalbeth N, Callan MF. A subset of natural killer cells is greatly expanded within inflamed joints. Arthritis Rheum. 2002;46(7):1763–1772. doi: 10.1002/art.10410
   PubMed Web of Science ®Google Scholar
• Schierloh P, Yokobori N, Alemán M, et al. Increased susceptibility to apoptosis of CD56dimCD16+ NK cells induces the enrichment of IFN-gamma-producing CD56bright cells in tuberculous pleurisy. J Immunol. 2005;175(10):6852–6860. doi: 10.4049/jimmunol.175.10.6852
   PubMed Web of Science ®Google Scholar
• Wilkinson R BMPL, Wang X, et al. Interferon-γ production by tubulointerstitial human CD56bright natural killer cells contributes to renal fibrosis and chronic kidney disease progression. Kidney Int. 2017;92(1):79–88. doi: 10.1016/j.kint.2017.02.006
   PubMed Web of Science ®Google Scholar
• Hefeneider SH, Conlon PJ, Henney CS, et al. In vivo interleukin 2 administration augments the generation of alloreactive cytolytic T lymphocytes and resident natural killer cells. J Immunol. 1983;130(1):222–227.
   PubMed Web of Science ®Google Scholar
• Fehniger TA, Cooper MA, Nuovo GJ, et al. CD56bright natural killer cells are present in human lymph nodes and are activated by T cell-derived IL-2: a potential new link between adaptive and innate immunity. Blood. 2003;101(8):3052–3057. doi: 10.1182/blood-2002-09-2876
   PubMed Web of Science ®Google Scholar
• Wong JL, Berk E, Edwards RP, et al. IL-18-primed helper NK cells collaborate with dendritic cells to promote recruitment of effector CD8+ T cells to the tumor microenvironment. Cancer Res. 2013;73(15):4653–4662. doi: 10.1158/0008-5472.CAN-12-4366
   PubMed Web of Science ®Google Scholar
• Shan NN, Jiang YJ, Sui XH, et al. The study of IL-18 and IL-18BP balance in aplastic anemia. Zhonghua Xue Ye Xue Za Zhi. 2011;32(11):783–785.
   PubMedGoogle Scholar
• Takeda K, Tsutsui H, Yoshimoto T, et al. Defective NK cell activity and Th1 response in IL-18-deficient mice. Immunity. 1998;8(3):383–390. doi: 10.1016/S1074-7613(00)80543-9
   PubMed Web of Science ®Google Scholar
• Chalifour A, Jeannin P, Gauchat JF, et al. Direct bacterial protein PAMP recognition by human NK cells involves TLRs and triggers alpha-defensin production. Blood. 2004;104(6):1778–1783. doi: 10.1182/blood-2003-08-2820
   PubMed Web of Science ®Google Scholar
• Nielsen N, Ødum N, Ursø B, et al. Cytotoxicity of CD56(bright) NK cells towards autologous activated CD4+ T cells is mediated through NKG2D, LFA-1 and TRAIL and dampened via CD94/NKG2A. PLoS One. 2012;7(2):e31959. doi: 10.1371/journal.pone.0031959
   PubMed Web of Science ®Google Scholar
• Morandi F, Horenstein AL, Chillemi A, et al. CD56brightCD16- NK cells produce adenosine through a CD38-mediated pathway and act as regulatory cells inhibiting autologous CD4+ T cell proliferation. J Immunol. 2015;195(3):965–972. doi: 10.4049/jimmunol.1500591
   PubMed Web of Science ®Google Scholar